The future of opioid analgesics

American Journal of Pharmaceutical Education

Volumn 66, Issue 2, 2002, Pages 153-156

  Coop, Andrew ^a   MacKerell Jr , Alexander D ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 27944489762     PISSN: 00029459     EISSN: 15536467     Source Type: Journal    
DOI: None     Document Type: Review

References (29)

1. Martin, T.J. and Eisenach, J.C., "Pharmacology of opioid and nonopioid analgesics in chronic pain states," J. Pharmacol. Exp. Ther., 299, 811-817(2001).
2. Anderson, S. and Leikersfeldt, G., "Management of chronic non-malignant pain," Br. J. Clin. Pract., 50, 324-330(1996).
3. White, J.M. and Irvine, R.J., "Mechanisms of fatal opioid overdose," Addiction, 94, 961-972(1999).
4. Pappagallo M., "Incidence, prevalence, and management of opioid bowel dysfunction," Am. J. Surg., 182, S11-S18(2001)
5. Mancini, I. and Bruera, E., "Constipation in advanced cancer patients," Sup. Care Cancer, 6, 356-364(1998).
6. Aldrich, J.V., "Narcotic analgesics," Am. J. Pharm. Educ., 57, 153-161(1993).
7. Portoghese, P.S., "Impact of recombinant DNA technology and molecular modeling on the practice of medicinal chemistry: structure-activity analysis of opioid ligands," Am. J. Pharm. Educ., 63, 342-347(1999).
8. Casy, A.F. and Parfitt, R.T., Opioid Analgesics, Plenum Press, New York NY (1986).
9. Casy, A.F., The Steric Factor in Medicinal Chemistry: Dissymmetric Probes of Pharmacological Receptors, Plenum Press, New York NY (1993) pp.429-548.
10. Lasagna, L. and Beecher, H.K., "The analgesic effectiveness of nalorphine and nalorphine-morphine combinations in man," J. Pharmacol. Exp. Ther., 112, 356-363(1954).
11. Martin, W.R., "Opioid antagonists," Pharmacol. Rev., 19, 463-521(1967).
12. Quiron, R., Bowen, W.D., Itzahak, Y., Junien, J.L., Musacchio, J.M., Rothman, R.B., Su, T.P., Tam, S.W. and Taylor, D.P.A., "A proposal for the classification of sigma binding sites," Trends Pharmacol. Sci., 13, 85-86(1992).
13. Kieffer, B.L., "Recent advances in molecular recognition and signal transduction of active peptides: receptors for opioid receptors," Cell Mol. Neurobiol., 15, 615-635(1995).
14. Devi, L.A., "Heterodimerization of G-protein-coupled receptors: Pharmacology, signaling and trafficking," Trends Pharmacol. Sci., 22, 532-537(2001).
15. Portoghese, P.S., "From models to molecules: Opioid receptor dimers, bivalent ligands, and selective opioid receptor probes," J. Med. Chem., 44, 2259-2269(2001).
16. Barlocco, D., Cignarella, G., Giardina, G.A.M. and Toma, L., "The opioid-receptor-like 1 (ORL-1) as a potential target for new analgesics," Eur. J. Med. Chem., 35, 275-282(2000).
17. Peters, G.R. and Gaylor, S., "Human central nervous system (CNS) effects of a selective kappa opioid agonist," Clin. Pharmacol. Ther., 45, 130(1989).
18. Hong, E.J., Rice, K.C., Calderon, S., Woods, J.H. and Traynor, J.R., "Convulsive behavior of nonpeptide delta-opioid ligands: Comparison of SNC80 and BW373U86 in mice," Analgesia, 3, 269-276(1998).
19. Manara, L. and Bianchetti, A., "The central and peripheral influences of opioids on gastrointestinal propulsion," Ann. Rev. Pharmacol. Toxicol., 25, 249-273(1985).
20. Foss, J.F., "A review of the potential role of methylnaltrexone in opioid bowel dysfunction," Am. J. Surg., 182, S19-S26(2001)
21. Kotake, A.N., Kuwahara, S.K., Burton, E., McCoy, C.E. and Goldberg, L.I., "Variations in demethylation of N-Methylnaltrexone in mice, rats, dogs and humans," Xenobiotica, 19, 1247-1254(1989).
22. Schmidt, W.K., "Alvimopan (ADL 8-2698) is a peripheral opioid antagonist," Am J. Surg., 182, S27-S38(2001).
23. Yaksh, T.L., "Pharmacology and mechanism of opioid analgesic activity," Acta Anaesthesiol. Scand., 41, 94-111(1997).
24. Kumar, V., Marella, M.A., Cortes-Burgos, L., Chang, A.C., Cassel, J.A., Daubert, J.D., DeHaven, R.N., DeHaven-Hudkins, D.L., Gottshall, S.L., Mansson, E. and Maycock, A.L., "Arylacetamides as peripherally restricted kappa opioid receptor agonists," Bioorg. Med. Chem. Lett., 10, 2567-2570(2000).
25. Dondio, G., Ronzoni, S. and Petrillo, P, "Non-peptide delta opioid agonists and antagonists," Exp. Opin. Ther. Pat., 7, 1075-1098(1997).
26. Coop, A. and Jacobson, A.E., "The LMC delta opioid recognition pharmacophore: comparison of SNC80 and Oxymorphindole," Bioorg. Med. Chem. Lett., 9, 357-362(1999).
27. Friedman, J.D. and Dello Bueno, F.A., "Opioid antagonists in the treatment of opioid-Induced constipation and pruritus," Ann. Pharmacother., 35, 85-91(2001).
28. Schiller, P.W., Fundytus, M.E., Merovitz, L., Weltrowska, G., Nguyen, T.M.D., Lemieux, C., Chung, N.N. and Coderre, T.J., "The opioid mu agonist/delta antagonist DIPP-NH2[psi] produces a potent analgesic effect, no physical dependence, and less tolerance than morphine in rats," J. Med. Chem., 42, 3520-3538(1999).
29. Anantham, S., Kezar, H.S., Carter, R.L., Saini, S.K., Rice, K.C., Wells, J.L., Davis, P., Xu, H., Dersch, C.M., Bilsky, E.J., Porreca, F. and Rothman, R.B., "Synthesis, opioid receptor binding, and biological activities of naltrexone-derived pyrido- and pyrimido-morphinans," J. Med. Chem., 42, 3527-3538(1999).